Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 16/20 | 0.58 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.53 |
| ▸ | MICA | Q29983 | 2/20 | 0.53 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938745 | 1.00 | MTTP (0.58) | MTTPKLRK1MICARAET1LMEN1 | |
| SCHEMBL4941165 | 0.94 | MTTP (0.60) | MTTPKLRK1MICARAET1LMEN1 | |
| SCHEMBL4941159 | 0.94 | MTTP (0.60) | MTTPKLRK1MICARAET1LMEN1 | |
| SCHEMBL14027915 | 0.93 | MTTP (0.50) | MTTPKLRK1MICARAET1LMEN1 | |
| SCHEMBL14027948 | 0.93 | MTTP (0.54) | MTTPKLRK1MICARAET1LMEN1 | |
| SCHEMBL13961193 | 0.91 | MTTP (0.49) | MTTPKLRK1MICARAET1LMEN1 | |
| SCHEMBL4932951 | 0.90 | KLRK1 (0.56) | MTTPKLRK1MICARAET1L | |
| SCHEMBL4932957 | 0.90 | KLRK1 (0.56) | MTTPKLRK1MICARAET1L | |
| SCHEMBL14027905 | 0.90 | MTTP (0.50) | MTTPKLRK1MICARAET1L | |
| SCHEMBL14027877 | 0.89 | MTTP (0.55) | MTTPMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | MTTP 1/4885KLRK1 3791/4885MICA 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.